TxCell hires a Novartis CAR-T researcher, AbbVie rejects Ablynx, Merck KGaA dumps an Apitope asset and more.

Roche has opted to discontinue the development of the candidate as a cancer monotherapy on a Phase II trial failure.

BlackThorn aims to succeed in the treacherous neuro territory by using physiological measures, rather than just a qualitative clinician assessment, to better…

Organ-on-a-chip player Emulate has added $17 million to its Series B round and landed a deal with Covance.

Bigfoot Biomedical reeled in $35.5 million in Series A funding, which it will use to push its automated insulin delivery service through the last stages of…

Rigel Pharmaceuticals fell about 35% in early trading on news that a second Phase III trial for its fostamatinib missed the primary endpoint.

Propeller Health snatched up $21.5 million in Series C financing that will drive the expansion of its digitally guided therapy platform.

An expert panel that advises the FDA has voted 14-4 that its experimental nocturia med be recommended for approval.